Independent Scientific Validation of The Fountain of Youth Lifestyle Tripeptide Collagen
Independently tested by a leading European university using pharmaceutical-grade laboratory models.
In-Vitro & In-Situ Studies:
FoYL’s tripeptide collagen has undergone independent, third-party laboratory testing to evaluate not just composition, but functional biological performance — something rarely done for collagen ingredients.
The studies were conducted by:
Università degli Studi di Milano
Dipartimento di Scienze Farmaceutiche (DiSFaRM)
Final Scientific Report Date: 27 June 2025
What These Studies Confirm - And Why It Matters:
Independent laboratory testing demonstrated that FoYL’s collagen is fundamentally different from standard collagen products.
Rather than acting solely as a source of amino acids, FoYL’s ultra-low molecular weight tripeptide collagen was shown to behave as a bioactive peptide system, interacting with key metabolic and vascular pathways under controlled laboratory conditions.
Key Outcomes from the Independent Testing:
Up to 5× Higher Predicted Bioactivity:
Advanced peptide mapping showed that FoYL’s tripeptide collagen exhibits up to five times greater predicted biological activity compared with conventional collagen peptides.
What this means for you:
More of the collagen you consume is biologically “active”, not just digested and discarded.
Precision Peptides for Superior Absorption:
- 300–500 Dalton molecular weight
-
Over 80% tripeptides
This size range aligns with the optimal zone for collagen peptide absorption and signalling, allowing peptides to be rapidly absorbed while retaining their functional activity.
What this means for you:
Your body can absorb and use this collagen more efficiently than standard, larger collagen peptides.
Supports Natural Metabolic Signalling:
Laboratory testing showed that FoYL’s tripeptide collagen:
- Stimulated pathways involved in natural satiety signalling
- Helped maintain balanced post-meal metabolic responses
- Demonstrated activity at realistic daily intake levels
What this means for you:
Support for metabolic balance — not through stimulants or drugs, but by working with your body’s own signalling systems.
Supports Healthy Circulation Pathways:
The studies also demonstrated interaction with enzyme systems involved in:
- Vascular relaxation
- Blood flow regulation
What this means for you:
FoYL collagen supports whole-body wellbeing, not just skin, hair, or joints.
Proven to Remain Active in the Gut:
Importantly, FoYL’s tripeptide collagen retained biological activity in human intestinal cell models (in-situ testing).
Most collagen products are never tested this way of to this level.
What this means for you:
This collagen doesn’t just look good on paper — it remains active where absorption actually occurs.
Gentle & Well Tolerated:
- High cell viability observed in testing
- Confirms compatibility under laboratory conditions
What this means for you:
Designed for daily use as part of a long-term wellness routine.
Why This Sets FoYL Collagen Apart
Most collagen products rely on:
- Generic hydrolysed collagen
- Amino-acid profiles
- Broad, non-specific claims
FoYL’s collagen is supported by independent university-led testing demonstrating:
- Higher bioactivity
- Better absorption potential
- Functional metabolic and vascular relevance
This positions FoYL collagen as a next-generation, precision-designed collagen, not a commodity protein powder.
Reference:
Independent scientific evaluation conducted by
Università degli Studi di Milano – Dipartimento di Scienze Farmaceutiche (DiSFaRM)
Final report dated 27.06.2025
Are you ready to downsize your scoop - and upsize your results?
Additional Scientific Studies:
Please Note: Not all related to Tripeptide Collagen
#
|
First author, year (journal)
|
Key finding (dose / model)
|
Free full-text / DOI
|
| 1 |
Inoue 2016 (J Sci Food Agric) |
5 g day⁻¹ “NGI” bovine HC for 8 weeks ↑ skin hydration (+7-12 %), elasticity (+4-9 %), ↓ wrinkle depth (-8 %) in 56 women (DB-RCT). |
PubMed: https://pubmed.ncbi.nlm.nih.gov/26840887 Europe PMC
|
| 2 |
Ohara 2007 (J Agric Food Chem) |
Human crossover study (5 ♂) showed plasma peak 20-60 nmol mL⁻¹ Hyp-di/tripeptides 1-2 h after 10 g bovine HC. |
https://pubmed.ncbi.nlm.nih.gov/17253720 Europe PMC
|
| 3 |
Iwai 2005 (J Agric Food Chem) |
First identification of food-derived Pro-Hyp in human blood after 10 g porcine/bovine HC; proves intact tripeptide absorption. |
https://pubmed.ncbi.nlm.nih.gov/16076145 Europe PMC
|
| 4 |
Ichikawa 2010 (Int J Food Sci Nutr) |
9 g day⁻¹ bovine HC for 4 weeks: plasma Pro-Hyp 4-fold ↑; confirms dose-dependence of tripeptide appearance. |
https://pubmed.ncbi.nlm.nih.gov/19961355 Europe PMC
|
| 5 |
Watanabe-Kamiyama 2010 (J Agric Food Chem) |
Rats given low-MW bovine HC (average 3 kDa): ↑ femoral bone mineral content (+7 %). |
https://pubmed.ncbi.nlm.nih.gov/19957932 Europe PMC
|
| 6 |
Yamamoto 2016 (Biol Pharm Bull) |
Human study comparing purified CTP-50 vs generic HC: plasma & urinary Pro-Hyp ↑ proportional to Gly-Pro-Hyp intake. |
https://pubmed.ncbi.nlm.nih.gov/26934933 Europe PMC
|
| 7 |
Proksch 2014 – VERISOL® (Skin Pharmacol Physiol) |
2.5 g bovine-hide BCP for 8 weeks ↓ eye-wrinkle volume by -20 %; procollagen I +65 %. |
https://pubmed.ncbi.nlm.nih.gov/24401291 Europe PMC
|
| 8 |
Proksch 2013 (Skin Pharmacol Physiol) |
2.5 or 5 g bovine HC for 8 weeks ↑ skin elasticity 15 %; effect persisted 4 weeks post-intervention. |
https://pubmed.ncbi.nlm.nih.gov/23949208 Europe PMC
|
| 9 |
Song 2013 (Clin Interv Aging) |
3 g collagen tripeptide for 12 weeks ↑ skin hydration (+28 %) & elasticity (+19 %) in healthy adults. |
https://pubmed.ncbi.nlm.nih.gov/24131075 Europe PMC
|
| 10 |
Hexsel 2017 (J Cosmet Dermatol) |
2.5 g bovine BCP × 24 weeks: ↑ nail growth rate (+12 %) & ↓ fragility (-42 %). |
https://pubmed.ncbi.nlm.nih.gov/28786550 Europe PMC
|
Summaries:
#
|
Study & model
|
What they measured
|
Direction of the main result
|
| 1 |
Inoue 2016 – 8-week DB-RCT, 56 women, 5 g/day bovine HC |
Corneometer skin hydration, Cutometer elasticity, fringe-projection wrinkle depth |
↑ Hydration (+7-12 %), ↑ elasticity (+4-9 %), ↓ wrinkle depth (-8 %) vs placebo ndlabs.com
|
| 2 |
Ohara 2007 – single-dose crossover PK, 5 men, 10 g bovine HC |
Plasma levels of Hyp-di/tri-peptides |
Peaks of 20-60 nmol mL-¹ Pro-Hyp/Hyp-Gly at 1-2 h post-dose (none at baseline) Europe PMC
|
| 3 |
Iwai 2005 – single-dose PK, 5 volunteers, 10 g porcine/bovine HC |
Identification of intact tripeptides in serum |
First proof of Pro-Hyp appearance in human blood after oral collagen (positive mechanistic outcome) skinglow.com.ar
|
| 4 |
Ichikawa 2010 – dose-escalation PK, 4 volunteers |
Dose-response of plasma Hyp-peptides (30–385 mg kg-¹) |
Clear, linear ↑ in peptide Cmax with higher doses (6 → 33 nmol mL-¹) Europe PMC
|
| 5 |
Watanabe-Kamiyama 2010 – ovariectomised-rat model, 4 wks LMW bovine HC |
Femoral bone organic content & BMC |
↑ Bone organic matter and BMC (+7 %) vs controls; protective against osteoporosis Medscape
|
| 6 |
Yamamoto 2016 – human crossover, 9 subjects, tripeptide-enriched CTP vs generic HC |
Plasma & urinary Gly-Pro-Hyp/Pro-Hyp |
Higher and longer-lasting peptide levels with CTP-50; magnitude proportional to tripeptide dose JSTAGE
|
| 7 |
Proksch 2014 – 114 women, 2.5 g VERISOL® for 8 wks |
3-D stereo wrinkle volume & dermal biopsies |
-20 % eye-wrinkle volume; +65 % procollagen-I vs placebo (p < 0.05) Europe PMC
|
| 8 |
Proksch 2013 – 69 women, 2.5 / 5 g collagen peptides for 8 wks |
Cutometer elasticity (R2) |
+15 % elasticity at both doses; effect persisted 4 wks after stopping Europe PMC
|
| 9 |
Song 2013 (Kim BJ) – 64 adults, 3 g collagen tripeptide 12 wks |
Hydration & elasticity vs control |
+28 % hydration, +19 % elasticity; both significant vs control Europe PMC
|
| 10 |
Hexsel 2017 – 25 women, 2.5 g VERISOL® 24 wks (open-label) |
Nail growth rate & brittleness |
+12 % growth rate, -42 % cracked/brittle nails; 64 % “overall improvement” by physician assessment Europe PMC
|
